Adaptive Biotechnologies (NASDAQ:ADPT) Stock: Insider Susan Bobulsky Sells 6,444 Shares

Posted by Geri Gentry on Oct 10th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Susan Bobulsky sold 6,444 shares of the stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $30.00, for a total value of $193,320.00. Following the transaction, the insider directly owned 389,350 shares of the company’s stock, valued at approximately $11,680,500. The trade was a 1.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

On Tuesday, September 15th, Susan Bobulsky sold 1,195 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $27.00, for a total value of $32,265.00.
On Monday, August 10th, Susan Bobulsky sold 3,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.00, for a total value of $75,000.00.
On Thursday, July 30th, Susan Bobulsky sold 1,299 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.00, for a total value of $31,176.00.

Adaptive Biotechnologies Trading Up 1.5%

Shares of ADPT stock opened at $26.49 on Friday. The stock has a 50-day simple moving average of $26.06 and a 200 day simple moving average of $20.08. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $30.74. The stock has a market capitalization of $4.23 billion, a P/E ratio of -64.61 and a beta of 2.09. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%. The business had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same quarter last year, the firm posted ($0.17) earnings per share. Adaptive Biotechnologies’s revenue was up 21.5% compared to the same quarter last year. On average, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.40 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ADPT shares. The Goldman Sachs Group initiated coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 29th. They issued a “buy” rating and a $35.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. National Bank Financial set a $34.00 price target on Adaptive Biotechnologies in a report on Tuesday, September 22nd. Guggenheim increased their price objective on Adaptive Biotechnologies from $25.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Finally, Morgan Stanley raised their price objective on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.94.

Read Our Latest Analysis on Adaptive Biotechnologies

Institutional Trading of Adaptive Biotechnologies

Hedge funds have recently modified their holdings of the business. Arizona State Retirement System lifted its stake in Adaptive Biotechnologies by 1.3% in the 2nd quarter. Arizona State Retirement System now owns 31,866 shares of the company’s stock worth $684,000 after acquiring an additional 416 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Adaptive Biotechnologies by 6.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after acquiring an additional 941 shares in the last quarter. Assetmark Inc. grew its stake in Adaptive Biotechnologies by 46.4% during the 1st quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after acquiring an additional 1,401 shares in the last quarter. Nykredit A S acquired a new position in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $31,000. Finally, Allworth Financial LP acquired a new position in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $35,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and therapeutic applications. Its technologies analyze immune-cell receptors, including T-cell and B-cell receptors, to help identify and measure immune responses associated with cancer, infectious diseases and other conditions.

The company’s product portfolio includes immunoSEQ, a research and clinical platform for immune-repertoire sequencing, and clonoSEQ, a diagnostic test used to detect and monitor measurable residual disease in certain blood cancers.